Skip to main content
Premium Trial:

Request an Annual Quote

Abbott Licenses Epigenomics' Methylation Biomarker IP for Cancer IVD

NEW YORK (GenomeWeb News) - Abbott and Epigenomics have penned a non-exclusive license and collaboration agreement to develop a colorectal cancer diagnostic based on Epigenomics' intellectual property, Epigenomics said today.
 
Under the terms of the agreement, Abbott has licensed worldwide rights to Epigenomics’ DNA methylation biomarker Septin 9, which the companies plan to develop into an in vitro diagnostic blood test for early detection of colorectal cancer.
 
The companies plan to launch a CE-marked test in Europe in 2009, and plan to file for approval with the US Food and Drug Administration in 2010.
 
Under the deal, Abbott will give Epigenomics and up-front fee, milestone payments, and royalties from sales of the test. A side provision in the agreement allows Abbott to evaluate Epigenomics' "other proprietary biomarkers for additional cancer indications."
 
Epigenomics said this test will be the first cancer diagnostic to run on Abbott's m2000 platform.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.